Summary
Edwards Lifesciences Corporation (EW) has filed an 8-K report on October 30, 2025, to disclose its financial results for the third quarter of 2025. The report primarily references a press release, dated October 30, 2025, which contains the detailed financial outcomes for the period. Investors should refer to this press release (Exhibit 99.1) for comprehensive information regarding the company's performance, including revenue, profitability, and any key operational metrics. This filing serves as notification of these results and does not represent new financial statements being filed directly within the 8-K. The furnished information under Item 2.02, including the press release, is not considered 'filed' for the purposes of the Securities Exchange Act of 1934, meaning the company retains protection against potential liabilities associated with such information until officially filed in subsequent reports. Investors are encouraged to review the press release for a full understanding of the company's third-quarter performance.
Key Highlights
- 1Edwards Lifesciences (EW) filed an 8-K on October 30, 2025, announcing third-quarter 2025 financial results.
- 2The core of the filing is a press release dated October 30, 2025, provided as Exhibit 99.1.
- 3Investors need to consult the referenced press release for detailed financial performance and operational insights.
- 4The filing incorporates the press release by reference.
- 5Information furnished under Item 2.02, including the press release, is not deemed 'filed' under the Securities Exchange Act of 1934.
- 6The filing includes a Cover Page Interactive Data File in Inline XBRL format.